Day 2 :
Keynote Forum
Royida Al Marastani
SEHA-Ambulatory Healthcare Services, UAE
Keynote: Bioavailability and drug selection
Time : 10:00-11:00
Biography:
Royida Al Marastani is a senior Pharmacist with more than thirty years of experience in the UAE in Abu Dhabi in Primary Health Centers (PHC), Urgent Care Center (UCC), Ambulatory Health Services (AHS) and MSc in Clinical Pharmacy UK. A lecturer from 2003 in Ministry of Health (MOH), in CPE/CME pharmacist’s program from 2011 in SEHA/ Ambulatory Healthcare Services (AHS). Conducting research, conference abstracts, invited presentations in the national & international conferences, focusing on pharmaceutical care based on safety and efficacy of the medications
Abstract:
Bioavailability is a pharmacokinetic term that describes the rate and extent to which the active drug ingredient is absorbed from a drug product and becomes available at the site of drug action. Since pharmacologic response is generally related to the concentration of drug at the receptor site, the availability of a drug from a dosage form is a critical element of a drug product’s clinical efficacy. However, drug concentrations usually cannot be readily measured directly at the site of drug.The availability of different formulations of the same drug substance given at the same strength and in the same dosage form poses a special challenge to health care professionals, making these issues very relevant to pharmacists in all practice settings. Since pharmacists play an important role in product-selection decisions, they must understand the principles and concepts of bioavailability and bioequivalence. Co administration of oral intake of herbs, supplements, foods and drugs with other drug(s) may affects pharmacokinetic or pharmacodynamics of the drugs. Although these interactions are often associated with undesired outcomes such as adverse drugs reactions, sub therapeutic effects or they can also produce potentially desired effects. Desired pharmacokinetic effects include enhancing of the bioavailability of a drug (i.e., by increasing the rate of the absorption and/or inhibiting metabolism)
- Workshop
Session Introduction
Royida Al Marastani
SEHA-Ambulatory Healthcare Services, UAE
Title: Drug interactions affecting drug bioavailability
Biography:
Royida Al Marastani is a senior pharmacist with more than thirty years of experience in the UAE in Abu Dhabi in Primary Health Centers (PHC), Urgent Care Center (UCC), Ambulatory Health Services (AHS) and MSc in Clinical Pharmacy UK. A lecturer from 2003 in Ministry of Health (MOH), in CPE/CME pharmacist’s program from 2011 in SEHA/ Ambulatory Healthcare Services (AHS). Conducting research, conference abstracts, invited presentations in the national & international conferences, focusing on pharmaceutical care based on safety and efficacy of the medications.
Abstract:
Drug-drug interactions (DDIs) are increased especially with polypharmacy patients leading to increased or decreased the clinical efficacy or increased the risk of the side effects or even the toxic effects.DDI can be classify into two classes pharmacokinetic and pharmacodynamic which affects the bioavailability of the drugs
Example 1:
H2 antagonists (e.g.ranitidine), antacids (e.g., aluminium hydroxide and sodium bicarbonate) and PPI (e.g., omeprazole, esomeprazole, pantoprazole) that increase the gastric pH lead to facilitate the absorption of beta-blockers .
Example 2:
Antifungal agents (e.g., ketoconazole or itraconazole), requires an acidic environment, therefore, their co-administration with drugs able to increase gastric pH, may cause a decrease in both dissolution and absorption of antifungal drugs. Therefore, antacid or anticholinergics, or PPI might be administered at least 2 h after the administration of antifungal agents.
Example 3:
The administration of drugs able to increase the gastric pH with ampicillin, atazanavir, clopidogrel, diazepam, methotrexate, vitamin B12, paroxetine and raltegravir are not recommended.
Example 4:
The administration of drugs that decrease the gastric pH (e.g., pentagastrin), may have an opposite effect.
Example 5:
Tetracyclines (e.g., doxycycline or minocycline) in the digestive tract can combine with metal ions (e.g., calcium, magnesium, aluminum, iron) to form complexes poorly absorbed. Consequently certain drugs (e.g., antacids, preparations containing magnesium salts, aluminum and calcium preparations containing iron) can significantly reduce the tetracyclines absorption.
Example 6:
Antacids reduce the absorption of fluoroquinolones (e.g., ciprofloxacin), penicillamines and tetracyclines, because the metal ions form complexes with the drug. So antacids and fluoroquinolones should be administered at least 2 h apart or more.
Example 7:
Metoclopramide, may accelerate gastric emptying, hence decreasing the absorption of digoxin and theophylline whereas it can accelerate the absorption of alcohol, acetylsalicylic acid, acetaminophen, tetracycline and levo-dopa.
- Clinical Research | Drug Discovery | Pharmacology | Pharmaceutical Formulations
Chair
Heyam Saad Ali
Dubai Pharmacy College, UAE
Co-Chair
Sudhir Kumar Sharma
New York University Abu Dhabi, UAE
Session Introduction
Sudhir Kumar Sharma
New York University Abu Dhabi, UAE
Title: Synthesis of Naproxen molecular clusters by super-critical CO2 processing
Biography:
Sudhir Kumar Sharma has completed his Masters in Physics and MTech in Materials from Department of Physics, Barkatullah University Bhopal, India. He has completed his PhD from the Indian Institute of Science Bangalore, India. He as a Post-doctratral Fellow attended Centre for Nano Science and Engineering (CeNSE), IISc. Bangalore, India. He has worked as a Research Associate at New York University Abu Dhabi, UAE and is currently working as a Research Scientist. He has more than 90 international journals and conferences publications
Abstract:
In pharmaceutical industry, poor water solubility and limited bioavailability has a major concern on new drug development. It is well established that the bioavailability of such drugs can be improved by reducing their particle size. A number of conventional strategies are available in literature for particle size reduction but they suffer with some disadvantages and handling concerns. Recently, supercritical CO2 (sc-CO2) based processes are found to be more promising for micronization of pharmaceuticals as they have successfully addressed the above concerns and offer additional advantages like economic, non-toxic, scalable, environmentally compatible and etc. In present studies, we report the synthesis of naproxen molecular clusters via supercritical CO2 drug formulation. These molecular clusters were collected in a special designed a two-stage collection vessel, cooled to liquid N2 temperatures, resulted embedding of drug molecular clusters in ‘dry ice’. Gradual transferring of the ‘dry ice’ into deionized water, resulted in the true solubilization of drug molecular clusters. Afterword’s, these solutions were drop-casted on silicon substrate and dried for overnight under ambient conditions, resulted in a stable, viscous films with liquid like behavior. Analytical characterizations showed that these solutions have retained their chemical and structural identity after sc-CO2 processing. This is interesting to note that raw naproxen powder is solid powder under ambient conditions with melting points of 154o C. Our observations are expected to explore the sc-CO2 processing strategy for other existing drug formulations and would open up new drug delivery platforms.
Amal Ahmed Abdel Nabbi Hassan
Dubai Pharmacy College, UAE
Title: The effect of mucoadhesive polymers in improving drug bioavailability & absorption
Biography:
Dr.Amal Ahmed Abdel nabbi Hassan, Dubai Pharmacy College, Dubai, UAE. . She has teaching research experience and high communication skills. She has been serving as an OCM and participating in many international conferences
Abstract:
The oral mucosa offers an interesting site for the application of dosage forms that release drugs within/throughout the oral mucosa, by assuring a high drug bioavailability for topic and systemic effects. The mucoadhesion is a complex phenomenon and the mucoadhesive bond consists of two different parts, the mucoadhesive polymers and the mucous substrate. In addition to factors related to the oral mucosa and oral environment features, the physical-chemical characteristics of mucoadhesive polymers must be also considered as factors influencing the mucoadhesive bonds
The study was conducted to formulate different types of MDDS, using mucoadhesive polymers (e.g. carbopols, sodium alginate, chitosan…) and have been utilized in different dosage forms in efforts to achieve systemic delivery of drugs through mucosal membrane.
Conclusion: Since a sustained drug release can be guaranteed only if dosage forms remain in contact with the oral site of absorption/application for a prolonged time, the development of mucoadhesive dosage forms is mandatory. They can prolong the residence time of the dosage form at the site of absorption thus enhance drug therapeutic efficacy.
Said Abdel Karim Abdel Hamid Mohamed
SEHA-Ambulatory Healthcare Services, UAE
Title: Gene therapy and it’s recent application
Biography:
Said is working as a clinical staff lead pharmacist with more than 8 years of experience as Hospital pharmacist, furthermore he worked as a Teaching Aids at Al Ahram Canadian university Egypt, as well as drug control specialist in antibiotics department at NODCAR (the national organization for drug control & research) currently he is working as pharmacist lead in Ambulatory Healthcare Services-SEHA, Participated in many local and international conferences, Said has certified as American board pharmacotherapy specialist (BCPS). He got his M.Sc. in clinical pharmacy in 2014 and in 2015 got his MBA from Torrens university/Abu Dhabi.
Abstract:
Gene therapy is one of the most advanced ways in threatening the most untreatable diseases and its simply when DNA is introduced into a patient to treat a genetic disease. The new DNA usually contains a functioning gene to correct the effects of a disease-causing mutation. Sometimes the whole or part of a gene is defective or missing from birth or a gene can change or mutate during adult life. Any of these variations can disrupt how proteins are made, which can contribute to health problems or diseases. In this presentation we will illustrate the basics of gene therapy and the most recent approved gene therapy products.
Biography:
Rahul A Hajare is Fellow of Indian Council of Medical Research, New Delhi, India. He is PhD student of reputed University Vinayaka Mission Research Foundation, Salem, Tamil Nadu. He is a winner of World Academic Championship-2017 in Pharmacy (Antiretroviral Therapy). He is among world's 500 most influential experts in pharmacy for the year 2017 on earth. He is also an alumni of The Yoga Institute Centenary Celebration Mumbai.
Abstract:
To highlight this important part of the research process, we asked research scientists to speak about their own experiences with failure. Research scientist explains why considers non-significant and negative studies to be important parts of publication history. Licensed data by USFDA Levofloxacin, but pregnancy category risk not ruled out. Levofloxacin identified by IUPAC (3S)-9-Fluor-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]chinolin-6-carbonsäure, by the end of 6-carboxylic acid group. Legal status is general prescription only. Levofloxacin was approved for medical use in the United States in 1996. It is on the world health organization's list of essential medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is about 0.44 to 0.95 USD per week of treatment. In the United States a week of treatment costs about 50 to 100 USD. As of 2016, the US Food and Drug Administration (FDA) recommended that "serious side effects associated with OH side antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, OH should be inherent impurity seen in levofloxacin. Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic. It is used to treat a number of bacterial infection including acute bacterial, sinusitis, Pneumonia and urinary infection, chronic prostatitis.
- Workshop
Session Introduction
Said Abdel Karim Abdel Hamid Mohamed
SEHA-Ambulatory Healthcare Services, UAE
Title: Assessment of antimicrobial agents in stewardship program
Biography:
Said is working as a clinical staff lead pharmacist with more than 8 years of experience as Hospital pharmacist, furthermore he worked as a Teaching Aids at Al Ahram Canadian university Egypt, as well as drug control specialist in antibiotics department at NODCAR (the national organization for drug control & research) currently he is working as pharmacist lead in Ambulatory Healthcare Services-SEHA, Participated in many local and international conferences, Said has certified as American board pharmacotherapy specialist (BCPS). He got his M.Sc. in clinical pharmacy in 2014 and in 2015 got his MBA from Torrens university/Abu Dhabi.
Abstract:
"To measure is to know." Measurement recently has become a cornerstone of benchmarking and scrutiny within healthcare. A successful antimicrobial stewardship should include SMART key measures considering measure the quality, the improvement and the impact of the program, in this workshop we are going to demonstrate the appropriate measures for Antimicrobial stewardship program in ambulatory care settings, the workshop includes a detailed examples on how to set and calculate those measures.
- Clinical Research | Drug Discovery | Pharmaceutical Formulations
Session Introduction
Rahul A Hajare
Indian Council of Medical Research, India
Title: Sexual species mix afterglow lasts up to three hours: Evidence for high prevalence and rapid transmission of skin pulp efflux among pure widow female individuals attending Non- Governmental Pharmaceutical Instituions in Pune, India
Biography:
Rahul A Hajare is Fellow of Indian Council of Medical Research, New Delhi, India. He is PhD student of reputed University Vinayaka Mission Research Foundation, Salem, Tamil Nadu. He is a winner of World Academic Championship-2017 in Pharmacy (Antiretroviral Therapy). He is among world's 500 most influential experts in pharmacy for the year 2017 on earth. He is also an alumni of The Yoga Institute Centenary Celebration Mumbai.
Abstract:
Tumble between the sheets may have lasted only for 30 seconds, but it turns out, the high got from sex lasts for three hours. A recent study of newly wed couples indicated that partners experience a sexual afterglow that lasts for up to three hours and this afterglow is linked with relationship quality over the long term. Researcher reported that sexual satisfaction remains elevated three hours after sex. And people with a stronger sexual afterglow, that has, people who report a higher level of sexual satisfaction three hours after sex, report higher levels of relationship satisfaction several months later. Researchers has theorized that sex plays a crucial role in pair bonding, but most adults report having sex with their partners every few days, not every day. Sex might provide a short-term boost to sexual satisfaction, sustaining the pair bond in between sexual experiences and enhancing partner’s relationship satisfaction over the long term. To test their hypothesis, the researchers examined data from two independent, longitudinal studies, one with 96 newly wed couples and another with 118 newlywed couples with different color. All of the couples has completed at least three consecutive days of a 14-day daily diary as part of a larger study. Every night, before going to bed, the newlyweds has asked to report independently whether they have sex with their partner that day. Regardless of the answer, they have asked to rate how satisfied with their sex life that day and how satisfied they have with their partner, their relationship and their marriage that day (on a 7-point scale, where 1=not at all, 7=extremely).
Rana Mhd Farid Sammour
Dubai Pharmacy College, UAE
Title: Optimization of Aceclofenac proniosomes by using mannitol as a carrier
Biography:
Rana Mhd Farid Sammouris lecturer in Pharmaceutics Department at Dubai Pharmacy College, UAE. She has completed her Master of Science in Pharmacy ( Msc Pharm ) in Pharmaceutical Technology from Ajman University , Ajman, UAE and Bachelor (Honor) in Pharmacy from Dubai Pharmacy College, UAE.
Abstract:
Aim is to optimize a free-flowing and stable proniosome formulation of Aceclofenac that is considered as a poorly water-soluble drug by using mannitol as a carrier. Slurry method were used for the preparation of the proniosomes by using span60, cholesterol, mannitol and Aceclofenac as a drug. Different characterization were done for the prepared proniosomes such as DSC, FTIR and flowability. While Entrapment Efficiency and Zetapotential with Zetasizer were done for the niosomes derived from Aceclofenac proniosomes after hydration. In vitro drug released were studied by using the diffusion membrane technique and percentage of drug release were analyzed by using HPLC method. The proniosomal powder were compatible and exhibited excellent flowability. The niosomes derived from